New rabies vaccine shows promise in preventing deadly infection
NCT ID NCT04594551
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tested a new rabies vaccine (VRVg-2) in 201 healthy adults in Thailand. Participants received the vaccine along with rabies antibodies, mimicking post-exposure treatment. The study measured immune response and safety, finding that the vaccine triggered protective antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Purified vero rabies vaccine - serum free (VRVg-2)
- What this could lead to
- If successful, this could provide a safer, effective rabies vaccine option for post-exposure prevention.
- What could go wrong
- This is a completed Phase 3 trial in healthy adults, not actual rabies patients. Real-world effectiveness and safety in infected individuals may differ.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RABIES (HEALTHY VOLUNTEERS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational site number 7640001
Bangkok, 10400, Thailand
-
Investigational site number 7640002
Bangkok, 10330, Thailand
-
Investigational site number 7640003
Bangkok, 10700, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Rabies vaccine booster still effective after 5 years, study to confirm
- New rabies shot could shield millions after bites
- Rabies vaccine batch check: will it pass the test?
- New rabies vaccine schedule tested in 2,000 volunteers
- Promising new rabies vaccine passes phase 3 test
- New rabies vaccine shows promise in large thai trial